Physician Awareness and Understanding of Primary Immunodeficiency Disorder: A Web-based Study

Not Applicable

• Conditions: Primary Immunodeficiency Disorder

• Registration Number: JPRN-UMIN000043088
• Lead Sponsor: Takeda Pharmaceutical Company Limited

Brief Summary

45% physicians knew PID's symptoms and clinical conditions but 20% was aware of the diagnostic criteria and the recommended treatment. After presentation of patients' medical history, 74% physicians suspected PID and 60% physicians considered labo-tests for Serum IgG (IgA:55%, IgM:56%,IgE:33%). 72 physicians currently treated PID and 33% physicians who treated PID answered they control; serum immunoglobulin G trough level at 400-500 mg/dL, which is lower than the globally recommended standard value.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-22
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 355

Inclusion Criteria

Not provided

Exclusion Criteria

1) Have less than 2 year of practice excluding training period 2) Work in a facility other than clinics, university hospitals, general hospitals and; national and public hospitals 3) Currently treating 0 outpatients and inpatients

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the level of awareness of PID and understanding the diagnostic flow in PID in clinical practice

Secondary Outcome Measures

Name	Time	Method
To determine the DDx between PID w/o IgG deficits including current treatment of PID To determine the awareness and usefulness of TIPs(10 warning signs) to consider PID in clinical settings.